Yunhan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunhan Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Aitian Li
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications - Li Yang
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications - Yi Zhang
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Beibei Xu
CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
1 shared publicationChenyi Zhou
Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publicationHaiqing Bai
Henan Academy of Innovations in Medical Science, Zhengzhou, China
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Macrophage-derived fibronectin suppresses antitumor immunity via tissue stiffening and immunosuppressive cell induction in cancer mouse models
Both tumor-associated macrophage (TAM) and tumor stiffness may support immunosuppression and limit immunotherapy response, particularly in non-small cell lung cancer (NSCLC). TAMs influence extracellular matrix (ECM) remodeling, but whether they also affect tumor stiffness, or are regulated by mechanical signals in turn, remains to be investigated. Here, we use single-cell transcriptomics of primary NSCLC samples to show that TAMs are associated with an immunosuppressive niche and are also a major source of the ECM component fibronectin (FN1). Mechanistically, macrophage-specific FN1 deficiency induces pro-inflammatory macrophages in a subcutaneous tumor mouse model, reduces ECM stiffness, increases lymphocyte infiltration into tumors, strengthens antitumor immunity, and enhances immune checkpoint blockade efficacy. Within TAMs, FN1-mediated cytoskeleton assembly and autophagy induction impair macrophage glycolysis by inhibiting the RAC1-mTOR axis, thereby limiting the antitumor activity of macrophages. Collectively, these findings highlight macrophage-derived FN1 as a mechanical cue for aggravating immunosuppression and as an intervention target to supplement immunotherapy in NSCLC.
- 22 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMacrophage-derived fibronectin suppresses antitumor immunity via tissue stiffening and immunosuppressive cell induction in cancer mouse models
Both tumor-associated macrophage (TAM) and tumor stiffness may support immunosuppression and limit immunotherapy response, particularly in non-small cell lung cancer (NSCLC). TAMs influence extracellular matrix (ECM) remodeling, but whether they also affect tumor stiffness, or are regulated by mechanical signals in turn, remains to be investigated. Here, we use single-cell transcriptomics of primary NSCLC samples to show that TAMs are associated with an immunosuppressive niche and are also a major source of the ECM component fibronectin (FN1). Mechanistically, macrophage-specific FN1 deficiency induces pro-inflammatory macrophages in a subcutaneous tumor mouse model, reduces ECM stiffness, increases lymphocyte infiltration into tumors, strengthens antitumor immunity, and enhances immune checkpoint blockade efficacy. Within TAMs, FN1-mediated cytoskeleton assembly and autophagy induction impair macrophage glycolysis by inhibiting the RAC1-mTOR axis, thereby limiting the antitumor activity of macrophages. Collectively, these findings highlight macrophage-derived FN1 as a mechanical cue for aggravating immunosuppression and as an intervention target to supplement immunotherapy in NSCLC.
- Open Access
- 20 October 2025
- Published by Wiley in Advanced Science
- Vol. 13 (5) , e06995
TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4 + T and NK Cells
Tumor‐associated macrophages (TAMs) predominantly exert functions that facilitate tumor progression. Triggering receptor expressed on myeloid cell 2 (TREM2) is expressed in TAMs, playing a crucial role in mediating the immunosuppressive function of TAMs. The mechanisms by which TREM2 + TAMs promote tumor growth and inhibit anti‐tumor immunity remain unclear. Through single‐cell sequencing of tumor tissues derived from wild‐type and Trem2 knockout mice bearing subcutaneous lung cancer, it is found that TREM2 deletion hindered tumor growth, with a notable increase in and improved functionality of CD4 + T and natural killer (NK) cells in the tumor microenvironment. TREM2 deficiency led to ATP‐binding cassette transporter A1 (ABCA1) downregulation, causing cholesterol accumulation in TAMs and promoting a pro‐inflammatory phenotype. This results in increased chemokine (C‐X3‐C motif) ligand 1 (CX3CL1) secretion of macrophages, recruiting more CD4 + T and NK cells to the tumor site, enhancing the anti‐tumor response. After screening food and drug administration (FDA)‐approved drugs, bortezomib and ataluren are found to effectively inhibit TREM2 expression in TAMs, indicating a potential therapeutic strategy against TREM2. This study elucidates the mechanism by which TREM2 shapes the immunosuppressive microenvironment and promotes tumorigenesis, highlighting TREM2 as a target for cancer immunotherapy.
- 20 October 2025
- Published by Wiley in Advanced Science
- Vol. 13 (5) , e06995
Open AccessTREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4 + T and NK Cells
Tumor‐associated macrophages (TAMs) predominantly exert functions that facilitate tumor progression. Triggering receptor expressed on myeloid cell 2 (TREM2) is expressed in TAMs, playing a crucial role in mediating the immunosuppressive function of TAMs. The mechanisms by which TREM2 + TAMs promote tumor growth and inhibit anti‐tumor immunity remain unclear. Through single‐cell sequencing of tumor tissues derived from wild‐type and Trem2 knockout mice bearing subcutaneous lung cancer, it is found that TREM2 deletion hindered tumor growth, with a notable increase in and improved functionality of CD4 + T and natural killer (NK) cells in the tumor microenvironment. TREM2 deficiency led to ATP‐binding cassette transporter A1 (ABCA1) downregulation, causing cholesterol accumulation in TAMs and promoting a pro‐inflammatory phenotype. This results in increased chemokine (C‐X3‐C motif) ligand 1 (CX3CL1) secretion of macrophages, recruiting more CD4 + T and NK cells to the tumor site, enhancing the anti‐tumor response. After screening food and drug administration (FDA)‐approved drugs, bortezomib and ataluren are found to effectively inhibit TREM2 expression in TAMs, indicating a potential therapeutic strategy against TREM2. This study elucidates the mechanism by which TREM2 shapes the immunosuppressive microenvironment and promotes tumorigenesis, highlighting TREM2 as a target for cancer immunotherapy.